The content on this site is intended for healthcare professionals only
Prof Pasi Janne speaks to ecancer about the FLAURA2 study presented at WCLC 2023.
He explains the study enrolled 557 patients and randomised them 1:1 into two treatment arms: osimertinib plus chemotherapy or osimertinib monotherapy.The combination arm involved a regimen of osimertinib (80 mg daily) alongside pemetrexed and either cisplatin or carboplatin.
The results showed a hazard ratio of 0.62 (95% CI 0.49, 0.79; p<0.0001) for progression-free survival, signifying an 8.8-month enhancement in median progression-free survival.
Therefore, osimertinib plus chemotherapy demonstrated superior results than osimertinib alone for patients with EGFR-mutated advanced lung cancer.
Read the full news story here
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Latest in PARP inhibitors and combination therapies for prostate cancer
